Disturbance of iron metabolism in Parkinson's disease - Ultrasonography as a biomarker

Neurotoxicity Research

Volumn 9, Issue 1, 2006, Pages 1-13

  Berg, Daniela ^a,b   Hochstrasser, Helmine ^b   Schweitzer, Katherine J ^a   Riess, Olaf ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Ceruloplasmin; Iron; Parkinson's disease; Substantia nigra hyperechogenicity; Transcranial ultrasound

Indexed keywords

2 METHYLPENTANE DIISOCYANATE; 2-METHYLPENTANE-DIISOCYANATE; BIOLOGICAL MARKER; CERULOPLASMIN; FERRITIN; IRON; ISOCYANIC ACID DERIVATIVE;

ANIMAL; BIOLOGICAL MODEL; ECHOGRAPHY; GENETIC VARIABILITY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MUTATION; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA;

ANIMALS; BIOLOGICAL MARKERS; CERULOPLASMIN; FERRITINS; HUMANS; IRON; ISOCYANATES; MODELS, BIOLOGICAL; MUTATION; PARKINSON DISEASE; SUBSTANTIA NIGRA; ULTRASONOGRAPHY; VARIATION (GENETICS);

EID: 33645929729     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033302     Document Type: Article

References (86)

1. Alam ZI, A Jenner, SE Daniel, AJ Lees, N Cairns, CD Marsden, P Jenner and B Halliwell (1997) Oxidative DNA damage in the parkinsonian brain: A selective increase in 8-hydroxyguanine in substantia nigra? J. Neurochem. 69, 1196-1203.
2. Attieh ZK, CK Mukhopadhyay, V Seshadri, NA Tripoulas and PL Fox (1999) Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J. Biol. Chem. 274, 1116-1123.
3. Bartzokis G, JL Cummings, CH Markham PZ Marmarelis, LJ Treciokas, TA Tishler, SR Marder and J Mintz (1999) MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. Magn. Reson. Imaging 17, 213-222.
4. Becker G, J Seufert, U Bogdahn, H Reichmann and K Reiners (1995) Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 45, 443-454.
5. Becker G, D Berg, WD Rausch, KW Lange, P Riederer and K Reiners (1999) Increased tissue copper and manganese content in primary adult-onset dystonia. Ann. Neurol. 46, 260-263.
6. Behnke S, D Berg, M Naumann and G Becker (2005) Differentiation of Parkinson's disease and atypical Parkinsonian syndromes by transcranial ultrasound. J. Neurol. Neurosurg. Psychiatry 76, 423-425.
7. Bennett MJ, JA Lebron and PJ Bjorkman (2000) Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor. Nature 403, 46-53.
8. Ben-Shachar D, P Riederer and MB Youdim (1991) Iron-melanin interaction and lipid peroxidation: Implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
9. Berg D and G Becker (2002) Perspectives of B-mode transcranial ultrasound. NeuroImage 15, 463-473.
10. Berg D, G Becker, B Zeiler, O Tucha, E Hofmann, M Preier, P Benz, W Jost, K Reiners and K Lange (1999a) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53, 1026-1031.
11. Berg D, C Grote, WD Rausch, M Mäurer, W Wesemann, P Riederer and G Becker (1999b) Iron accumulation of the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25, 901-904.
12. Berg D, C Siefker and G Becker (2001a) Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J. Neurol. 248, 684-689.
13. Berg D, B Jabs, U Merschdorf, H Beckmann and G Becker (2001b) Echogenicity of substantia nigra determined by trasncranial ultrasound correlates with severity of Parkinsonian symptoms induced by neuroleptic therapy. Biol. Psychiatry 50, 463-467.
14. Berg D, C Siefker, P Ruprecht-Dörfler and G Becker (2001c) Relationship of substantia nigra echogenicity and motor function in elderly subjects. Neurology 56, 13-17.
15. Berg D, W Roggendorf, U Schröder, R Klein, T Tatschner, P Benz, O Tucha, M Preier, KW Lange, K Reiners, M Gerlach and G Becker (2002) Echogenicity of the substantia nigra - association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch. Neurol. 59, 999-1005.
16. Berg D, MB Youdim and P Riederer (2004) Redox imbalance. Cell Tissue Res. 318, 201-213.
17. Berg D, B Merz, K Reiners, M Naumann and G Becker (2005) A five year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov. Disord. 20, 383-385.
18. Borie C, F Gasparini, P Verpillat, AM Bonnet, Y Agid, G Hetet, A Brice, A Durr, B Grandchamp and French Parkinson's Disease Genetic Study Group (2002) Association study between ironrelated genes polymorphisms and Parkinson's disease. J. Neurol. 249, 801-804.
19. Bosio S, M De Gobbi, A Roetto, G Zecchina, E Leonardo, M Rizzetto, C Lucetti, L Petrozzi, U Bonuccelli and C Camaschella (2002) Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations. Blood 100, 2246-2248.
20. Brooks DJ (1991) Detection of preclinical Parkinson's disease with PET. Geriatrics 46, Suppl. 1, 25-30.
21. Brooks DJ (1998) The early diagnosis of Parkinson's disease. Ann. Neurol. 44, Suppl. 1, 10-18.
22. Cairo G, E Rappocciolo, L Tacchini and L Schiaffonati (1991) Expression of genes for the ferritin H and L subunits in rat liver and heart. Biochem. J. 275, 813-816.
23. Costello DJ, SL Walsh, HJ Harrington and CH Walsh (2004) Concurrent hereditary haemochromatosis and idiopathic Parkinson's disease: A case report series. J. Neurol. Neurosurg. Psychiatry 75, 631-633.
24. Curtis ARJ, C Fey, CM Morris, LA Bindoff, PG Ince, PF Chinnery, A Coulthard, MJ Jackson, AP Jackson, DP McHale, D Hay, WA Barker, AF Markham, D Bates, A Curtis and J Burn (2001) Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat. Genet. 28, 350-354.
25. Dawson TM and VL Dawson (2003) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302, 819-822.
26. Deplazes J, K Schobel, H Hochstrasser, P Bauer, U Walter, S Behnke, J Spiegel, G Becker, O Riess and D Berg (2004) Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. J. Neural Transm. 111, 515-521.
27. De Rijk MC, C Tzourio, MMB Breteler, JF Dartigues, L Amaducci, S Lopez-Pousa, JM Manubens-Bertran, A Alperovitch and WA Rocca (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON collaborative study. J. Neurol. Neurosurg. Psychiatry 62, 10-15.
28. Dexter DT, CJ Carter, FR Wells, F Javoy-Agid, Y Agid, A Lees, P Jenner and CD Marsden (1989) Basal lipid peroxidation in sub- stantia nigra is increased in Parkinson's disease. J. Neurochem. 52, 381-389.
29. Dexter DT, J Sian, P Jenner and CD Marsden (1993) Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv. Neurol. 60, 273-281.
30. Double KL, GM Halliday, J Henderson, FM Griffiths, T Heinemann, P Riederer and M Gerlach (2003) The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp. Neurol. 184, 530-535.
31. Drysdale JW (1988) Human ferritin gene expression. Prog. Nucleic Acids Res. Mol. Biol. 35, 127-155.
32. Fearnley JM and AJ Lees (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114, 2283-2301.
33. Felletschin B, P Bauer, U Walter, S Behnke, J Spiegel, I Csoti, U Sommer, B Zeiler, G Becker, O Riess and D Berg (2003) Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra. Neurosci. Lett. 352, 53-56.
34. Forman MS, VM Lee and JQ Trojanowski (2003) Unfolding' pathways in neurodegenerative disease. Trends Neurosci. 26, 407-410.
35. Gandon Y, D Guyader, JF Heautot, MI Reda, J Yaouanq, T Buhe, P Brissot, M Carsin and Y Deugnier (1994) Hemochromatosis: Diagnosis and quantification of liver iron with gradient-echo MR imaging. Radiology 193, 533-538.
36. Gerlach M, D Ben-Shachar, P Riederer and MB Youdim (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases. J. Neurochem. 63, 793-807.
37. Gibb WR (1986) Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol. Appl. Neurobiol. 12, 223-234.
38. Gitlin JD (1998) Aceruloplaminemia. Pediatr. Res. 44, 271-276.
39. Goetz ME and M Gerlach (2004) Formation of radicals, in: Brain Damage and Repair (Herdegen T and J Delgado-Garcia, Eds.) (Kluwer: London), pp 135-164.
40. Golts N, H Snyder, M Frasier, C Theisler, P Choi and B Wolozin (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. J. Biol. Chem. 277, 16116-16123.
41. Haacke EM, NY Cheng, MJ House, Q Liu, J Neelavalli, RJ Ogg, A Khan, M Ayaz, W Kirsch and A Obenaus (2005) Imaging iron stores in the brain using magnetic resonance imaging. Magn. Reson. Imaging 23, 1-25.
42. Hallgren B and P Sourander (1958) The effect of age on non-haem iron in the human brain. J. Neurochem. 3, 41-51.
43. Harris ZL, Y Takahashi, H Miyajima, M Serizawa, RT MacGillivray and JD Giltin (1995) Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc. Natl. Acad. Sci. USA 92, 2539-2543.
44. Harrison PM and P Arrosio (1996) The ferritin: Molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta 1275, 161-203.
45. Hashimoto M, LJ Hsu, A Sisk, Y Xia, A Takeda, M Sundsmo and E Masliah (1998) Human recombinant NACP/alpha-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res. 799, 301-306.
46. Helenius A and M Aebi (2004) Roles of N-linked glycans in the endoplasmatic reticulum. Annu. Rev. Biochem. 73, 1019-1049.
47. Hentze MW and LC Kuhn (1996) Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA 93, 8175-8182.
48. Hochstrasser H, P Bauer, U Walter, S Behnke, J Spiegel, I Csoti, B Zeiler, A Bornemann, J Pahnke, G Becker, O Riess and D Berg (2004) Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 63, 1912-1917.
49. Hutchinson M and U Raff (2000) Structural changes of the substantia nigra in Parkinson's disease as revealed by MR imaging. Am. J. Neuroradiol. 21, 697-701.
50. Iova A, A Garmashov, N Andruchtchenko, M Kehrer, D Berg, G Becker and Y Garmashov (2004) Postnatal decrease in Substantia nigra echogenicity - implications for the pathogenesis of Parkinson's disease. J. Neurol. 251, 1451-1454.
51. Iwai K, RD Klausner and TA Rouault (1995) Requirements for iron-regulated degradation of the RNA binding protein, iron regulatory protein 2. EMBO J. 14, 5350-5357.
52. Jenner P (2001) Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci. 24, 245-247.
53. Kato J, K Fujikawa, M Kanda, N Fukuda, K Sasaki, T Takayama, M Kobune, K Takada, R Takimoto, H Hamada, T Ikeda and Y Niitsu (2001) A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am. J. Hum. Genet. 69, 191-197.
54. Klomp LW and JD Gitlin (1996) Expression of the ceruloplasmin gene in the human retina and brain: Implications for a pathogenic model in aceruloplasminemia. Hum. Mol. Genet. 5, 1989-1996.
55. Kohno S, H Miyajima and Y Takahashi (1999) Aceruloplasminemia with a novel mutation associated with parkinsonism. Neurogenetics 2, 237-238.
56. Kortekaas R, KL Leenders, JC van Oostrom, W Vaalburg, J Bart, AT Willemsen and NH Hendrikse (2005) Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57, 176-179.
57. LaVaute T, S Smith, S Cooperman, K Iwai, W Land, E Meyron-Holtz, SK Drake, G Miller, M Abu-Asab, M Tsokos, R Switzer 3rd, A Grinberg, P Love, N Tresser and TA Rouault (2001) Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27, 209-214.
58. Lyon E and EL Frank (2001) Hereditary hemochromatosis since discovery of the HFE gene. Clin. Chem. 47, 1147-1156.
59. Marnett LJ (2000) Oxyradicals and DNA damage. Carcinogenesis 21, 361-370.
60. Mondino F, P Filippi, U Magliola and S Duca (2002) Magnetic resonance relaxometry in Parkinson's disease. Neurol. Sci. 23, 87-88.
61. Montine KS, JF Quinn, J Zhang, JP Fessel, LJ Roberts 2nd, JD Morrow and TJ Montine (2004) Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem. Phys. Lipids. 128, 117-124.
62. Mukhopadhyay CK, ZK Attieh and PL Fox (1998) Role of ceruloplasmin in cellular iron uptake. Science 279, 714-717.
63. Münch G, D Schicktanz, A Behme, M Gerlach, P Riederer, D Palm and R Schinzel (1999) Amino acid specificity of glycation and protein - AGE crosslinking reactivities determined with a dipeptide SPOT library. Res. Nature Biotech. 17, 1006-1010.
64. Münch G, HJ Lüth, A Wong, T Arendt, E Hirsch, R Ravid and P Riederer (2000) Crosslinking of α-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation. J. Clin. Neuroanatomy 20, 253-257.
65. Oskai S, DA Johnson and E Frieden (1966) The possible role of the ferrous oxidase activity of ceruloplasmin in normal human serum. J. Biol. Chem. 241, 11490-11491.
66. Poon HF, V Calabrese, G Scapagnini and DA Butterfield (2004) Free radicals and brain aging. Clin. Geriatr. Med. 20, 329-359.
67. Qian ZM and Y Ke (2001) Rethinking the role of ceruloplasmin in brain iron metabolism. Brain Res. Brain Res. Rev. 35, 287-294.
68. Raff U, GM Rojas, I Huete and M Hutchinson (2003) Computer assessment of neurodegeneration in Parkinson disease using data fusion techniques with MR images. Acad. Radiol. 10, 1036-1044.
69. Riederer PF (2004) Views on neurodegeneration as a basis for neuroprotective strategies. Med. Sci. Monit. 10, RA287-RA290.
70. Riederer P and MBH Youdim (1993) Iron in Central Nervous System Disorders (Springer:VIenna).
71. Riederer P, WD Rausch, B Schmidt, P Kruzik, C Konradi, E Sofic, W Danielczyk, M Fischer and E Ogris (1988) Biochemical fundamentals of Parkinson's disease. Mt. Sinai J. Med. 55, 21-28.
72. Riederer P, E Sofic, WD Rausch, B Schmidt, GP Reynolds, K Jellinger and MB Youdim (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinsonian brains. J. Neurochem. 52, 515-520.
73. Ruprecht-Dörfler P, D Berg, O Tucha, P Benz, M Meier-Meitinger, GL Alders, KW Lange and G Becker (2003) Echogenicity of the substantia nigra in relatives of patients with sporadic Parkinson's disease. NeuroImage 18, 416-422.
74. Sanchez-Ramos JR, E Övervik and BN Ames (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2'-deoxyguano- sine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3, 197-204.
75. 18F]dopa positron emission tomography studies in an Irish kindred. Ann. Neurol. 32, 609-617.
76. Shachar DB, N Kahana, V Kampel, A Warshawsky and MB Youdim (2004) Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 46, 254-263.
77. Sofic E, P Riederer, H Heinsen, H Beckmann, GP Reynolds, G Hebenstreit and MB Youdim (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74, 199-205.
78. Stadtman ER (2001) Protein oxidation in aging and age-related diseases. Ann. NY Acad. Sci. 928, 22-38.
79. Tajima K, T Kawanami, R Nagai, S Horiuchi and T Kato (1999) Hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain. Neurology 53, 619-622
80. Thobois S, M Jahanshahi, S Pinto, R Frackowiak and P Limousin-Dowsey (2004) PET and SPECT functional imaging studies in Parkinsonian syndromes: From the lesion to its consequences. Neuroimage 23, 1-16.
81. Thompson K, S Menzies, M Muckenthaler, FM Torti, T Wood, SV Torti, MW Hentze, J Beard and J Connor (2003) Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J. Neurosci. Res. 71, 46-63.
82. Walter U, M Wittstock, R Benecke and D Dressler (2002) Substantia nigra echogenicity is normal in non-extrapyramidal disorders but increased in Parkinson's disease. J. Neural Transm. 109, 191-196.
83. Youdim MB, G Stephenson and D Ben Shachar (2004) Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: A lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann. NY Acad. Sci. 1012, 306-325.
84. Zayed J, S Ducic, G Campanella, JC Panisset, P Andre, H Masson and M Roy (1990) Environmental factors in the etiology of Parkinson's disease. Can. J. Neurol. Sci. 17, 286-2891.
85. Zecca L, M Gallorini, V Schunemann, AX Trautwein, M Gerlach, P Riederer, P Vezzoni and D Tampellini (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J. Neurochem. 76, 1766-1773.
86. Zecca L, D Berg, T Arzberger, P Ruprecht, WD Rausch, M Musico, T Tampellini, P Riederer, M Gerlach and G Becker (2005) In vivo detection of iron and neuromelanin by transcranial sonography a new approach for early detection of substantia nigra damage. Mov. Disord. June 28 [Epub ahead of print].